Health insurers rally after government lays out better-than-expected Medicare Advantage raise
Shares of major health insurers jumped early Tuesday after the federal government announced a better-than-expected 2026 payment increase for Medicare Advantage plans.
The Centers for Medicare and Medicaid Services said Monday after markets closed that final rates are expected to increase more than 5% in 2026.
That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note.
BTIG analyst David Larsen said separately that the final increase more than doubled what was initially proposed in January. He added that it likely accounts for higher care use that the program has seen recently.
Larsen also credited the new administration of President Donald Trump.
'The higher overall final rate is in line with our view that Republican administrations are generally more (Medicare Advantage)-friendly,' Larsen wrote. 'While fraud, waste, and abuse are certainly a focus of the new administration, we view the final rate notice as a positive surprise.'
Medicare Advantage plans are privately-run versions of the government-funded Medicare program mostly for people who are 65 and older.
Shares of the two largest Medicare Advantage plan providers, UnitedHealth Group Inc. and Humana Inc., climbed more than 7% and 14%, respectively, before markets opened Tuesday. Other insurance stocks like Elevance Health Inc. and Centene Corp. also jumped.
The health sector was among the biggest gainers in a broader market rebound early Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
List: Republican candidates for NJ governor
The Brief Nearly a dozen candidates are competing for the chance to succeed Gov. Murphy. In the Republican primary, former state Assemblyman Jack Ciattarelli has President Trump's endorsement. Primary election day is Tuesday, June 10. Polls close at 8 p.m. NEW JERSEY - Nearly a dozen candidates are competing in New Jersey for the chance to succeed term-limited Democratic Gov. Phil Murphy. MORE: Who is ahead in the NJ governor race? Polls, candidates, updates MORE: How to vote in New Jersey In the Republican primary, former state Assemblyman Jack Ciattarelli has President Donald Trump's endorsement. ***Click on each name to jump to their section. Jack Ciattarelli Jon Bramnick Mario Kranjac Justin Barbera Ciattarelli, a Somerville native and business founder, is making another run for New Jersey governor. This time, he has the backing of President Trump. Ciattarelli nearly unseated Murphy back in 2021 and finished second in the 2017 GOP primary. This time, he says he is focused on tackling New Jersey's affordability crisis, citing rising taxes, tolls, and fees. Spadea is an entrepreneur and host of the Bill Spadea Show on NJ101.5 FM. Spadea says he's focused on New Jersey's budget and ending the illegal immigration crisis, which he claims costs taxpayers too much. Bramnick says he wants to create a government efficiency panel with private residents and business leaders to identify waste and areas for improvement. He's been in the State Senate since 2022 and was an Assemblyman for nearly two decades prior from 2003-2021. Kranjac is the former mayor of Englewood Cliffs, serving from 2016 to 2024. He calls himself a political outsider determined to change Trenton. Since leaving office, he has continued as a corporate attorney and venture capitalist. Barbera is a contractor and real estate developer from Burlington County. A Marlton native, Barbera's career includes work as a general contractor, insurance claim mitigator, freight carrier, and owner-operator of a CDL A flatbed and commercial snow service operation. Primary election day is Tuesday, June 10. Polls close at 8 p.m. Click HEREfor more information. Emerson College Polling/PIX11/The Hill survey: According to a May survey, 44% of registered New Jersey Republican voters said they would vote for former state Assemblyman Jack Ciattarelli, while 18% support talk radio host Bill Spadea. A month ahead of the primary, 23% of GOP voters said they were undecided. SurveyUSA: The poll conducted in May only asked voters about Ciattarelli, who "has favorability ratings of 40%-36% among the broader electorate and 63%-19% among Trump voters," accordin gto the New Jersey Globe. Trump endorsement: President Trump has endorsed Ciattarelli in May and campaigned for him in a virtual rally.
Medscape
2 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
Chicago Tribune
2 hours ago
- Chicago Tribune
Terry Savage: AI used to guide seniors to Medicare programs
Does the concept of artificial intelligence intimidate you? Or do you figure it won't have much impact on your life, so why bother learning about it? Well, AI is definitely entering — and improving — your life, whether you choose it or not. When I first wrote about ChatGPT several years ago, AI was viewed as a powerful tool to collect information from huge databases and sort it out to provide answers to questions. Since then, AI has quickly morphed into a useful tool for business and individuals, creating accurate and life-like interactions that make outcomes easier. For example, the new Social Security commissioner, a former tech payments CEO, has announced that Social Security will soon be using AI in its call centers. If the idea of talking to a 'robot' sends chills down your spine, think again. In this column, I'll show you a company that is already using AI in its call center — and generating responses that truly make you think you're talking to a helpful person. A reality check It's a generational thing. When I want help after calling a toll-free number for product information or credit card adjustments or insurance issues, I want to talk to an intelligent human being. I guess there aren't enough to go around! One of my pet peeves is being transferred to a voice messaging system that tries to 'help' me decide how to get answers to a simple question. They offer five choices, none of which is helpful. Representative, please! The only thing worse than a voice-activated decision tree is getting transferred to a live person who just happens to live in a foreign country and who is obviously responding off a script. If I ask to talk to a supervisor, I'm told there is no supervisor available! Don't these companies care about their customers? (Insert your own swear word here!) Artificial intelligence that's real So I must say I was absolutely shocked to hear a demonstration of AI being used by eHealth to start the process of guiding seniors to the appropriate choices for Medicare programs. For many years, eHealth has been a popular health insurance marketplace that helps people find the right insurance coverage by comparison-shopping plans from more than 180 insurers for coverage ranging from Medicare Advantage and supplemental plans to individual and family health policies, along with other benefits such as dental and vision. Many people access eHealth through its website, Others use their toll-free number 1-800-EHEALTH (1-800-343-2584) to reach their licensed and helpful insurance agents. Getting to the agent licensed in your state of residence, and knowledgeable about your specific product request, could take a lot of time during busy days around Medicare enrollment. And what about calls that come in late at night? That's why eHealth created 'Alice' — an AI 'agent' who does not actually sell insurance policies but who asks relevant questions to direct you to the correct licensed agent. You'd swear that you are talking to a live person, since 'her' responses are not only appropriate but friendly. Listening to the demo that eHealth sent me, I was absolutely blown away. I knew that you'd want to hear the same thing, so if you are reading this column online at my website you can click on this link in the article. In this case, an audio demo is worth a thousand words! Even if you're not shopping for health insurance, I recommend listening to this short clip of an interaction between someone calling the toll-free line late at night and the AI agent, Alice. This company has taken AI to the next level. Suddenly, you'll understand how much more helpful an AI agent can be than a call center in the middle of nowhere! And, on a personal level, you'll see how AI has so much potential to change our lives for the better (yes, or for the worse). I spoke with Ketan Babaria, chief digital and AI officer of eHealth. He notes that while AI is not (yet) selling policies, it is making a big difference in their processes: 'Our new AI agents are trained to be patient, caring and sympathetic. As a result, we are making it easier and faster for people to start the shopping process for a Medicare plan, enabling them to more quickly connect with a licensed agent who can help them comparison shop for the right health coverage.' So the next time you hear that your call will be answered by AI, don't hang up in fear, hoping that the next time you'll get a 'real person.' Odds are that soon you'll be connecting with many AI agents. And the odds are even better that you'll get the correct answer from a compassionate robot than you'd get from the overworked and underinformed call center worker. That's The Savage Truth.
